|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wei KR, Yu X, Zheng RS, Peng XB, Zhang SW,
Ji MF, Liang ZH, Ou ZX and Chen WQ: Incidence and mortality of
liver cancer in China, 2010. Chin J Cancer. 33:388–394.
2014.PubMed/NCBI
|
|
3
|
Fan JH, Wang JB, Jiang Y, Xiang W, Liang
H, Wei WQ, Qiao YL and Boffetta P: Attributable causes of liver
cancer mortality and incidence in China. Asian Pac J Cancer Prev.
14:7251–7256. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kumar S, Tomooka Y and Noda M:
Identification of a set of genes with developmentally
down-regulated expression in the mouse brain. Biochem Biophys Res
Commun. 185:1155–1161. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Feng Y, Wang Y, Wang Z, Fang Z, Li F, Gao
Y, Liu H, Xiao T, Li F, Zhou Y, et al: The CRTC1-NEDD9 signaling
axis mediates lung cancer progression caused by LKB1 loss. Cancer
Res. 72:6502–6511. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Guerrero MS, Parsons JT and Bouton AH: Cas
and NEDD9 contribute to tumor progression through dynamic
regulation of the cytoskeleton. Genes Cancer. 3:371–381. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Han T, Yi XP, Liu B, Ke MJ and Li YX:
MicroRNA-145 suppresses cell proliferation, invasion and migration
in pancreatic cancer cells by targeting NEDD9. Mol Med Rep.
11:4115–4120. 2015.PubMed/NCBI
|
|
8
|
Morimoto K, Tanaka T, Nitta Y, Ohnishi K,
Kawashima H and Nakatani T: NEDD9 crucially regulates
TGF-β-triggered epithelial-mesenchymal transition and cell invasion
in prostate cancer cells, Involvement in cancer progressiveness.
Prostate. 74:901–910. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Feng J, Zhao J, Xie H, Yin Y, Luo G, Zhang
J, Feng Y and Li Z: Involvement of NEDD9 in the invasion and
migration of gastric cancer. Tumour Biol. 36:3621–3628. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jin Y, Li F, Zheng C, Wang Y, Fang Z, Guo
C, Wang X, Liu H, Deng L, Li C, et al: NEDD9 promotes lung cancer
metastasis through epithelial-mesenchymal transition. Int J Cancer.
134:2294–2304. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Štajduhar E, Sedić M, Leniček T, Radulović
P, Kerenji A, Krušlin B, Pavelić K and Kraljević Pavelić S:
Expression of growth hormone receptor, plakoglobin and NEDD9
protein in association with tumour progression and metastasis in
human breast cancer. Tumour Biol. 35:6425–6434. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xue YZ, Sheng YY, Liu ZL, Wei ZQ, Cao HY,
Wu YM, Lu YF, Yu LH, Li JP and Li ZS: Expression of NEDD9 in
pancreatic ductal adenocarcinoma and its clinical significance.
Tumour Biol. 34:895–899. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li P, Zhou H, Zhu X, Ma G, Liu C, Lin B
and Mao W: High expression of NEDD9 predicts adverse outcomes of
colorectal cancer patients. Int J Clin Exp Pathol. 7:2565–2570.
2014.PubMed/NCBI
|
|
14
|
Kondo S, Iwata S, Yamada T, Inoue Y,
Ichihara H, Kichikawa Y, Katayose T, Souta-Kuribara A, Yamazaki H,
Hosono O, et al: Impact of the integrin signaling adaptor protein
NEDD9 on prognosis and metastatic behavior of human lung cancer.
Clin Cancer Res. 18:6326–6338. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sasaki T, Iwata S, Okano HJ, Urasaki Y,
Hamada J, Tanaka H, Dang NH, Okano H and Morimoto C: Nedd9 protein,
a Cas-L homologue, is upregulated after transient global ischemia
in rats, Possible involvement of Nedd9 in the differentiation of
neurons after ischemia. Stroke. 36:2457–2462. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Guo W, Ren D, Chen X, Tu X, Huang S, Wang
M, Song L, Zou X and Peng X: HEF1 promotes epithelial mesenchymal
transition and bone invasion in prostate cancer under the
regulation of microRNA-145. J Cell Biochem. 114:1606–1615. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Edmonson H and Steiner PE: Primary
carcinoma of the liver: A study of 100 cases among 48,900
necropsies. Cancer. 7:4621954. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sobin LH and Fleming ID: TNM
classification of malignant tumors fifth edition (1997).
Histopathology. Cancer. 80:1803–1804. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cai MY, Zhang B, He WP, Yang GF, Rao HL,
Rao ZY, Wu QL, Guan XY, Kung HF, Zeng YX and Xie D: Decreased
expression of PinX1 protein is correlated with tumor development
and is a new independent poor prognostic factor in ovarian
carcinoma. Cancer Sci. 101:1543–1549. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
O'Neill GM, Seo S, Serebriiskii IG, Lessin
SR and Golemis EA: A new central scaffold for metastasis, Parsing
HEF1/Cas-L/NEDD9. Cancer Res. 67:8975–8979. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang Q, Wang HJ, Zhang DH, Ru GQ, He XJ
and Ma YY: High expression of HEF1 is associated with poor
prognosis in urinary bladder carcinoma. Onco Targets Ther.
7:1319–1326. 2014.PubMed/NCBI
|
|
22
|
Wang H, Mu X, Zhou S, Zhang J, Dai J, Tang
L, Xiao L, Duan Z, Jia L and Chen S: NEDD9 overexpression is
associated with the progression of and an unfavorable prognosis in
epithelial ovarian cancer. Hum Pathol. 45:401–408. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang SS, Wu LH, Liu Q, Chen KS and Zhang
XF: Elevated expression of NEDD9 is associated with metastatic
activity in gastric cancer. Onco Targets Ther. 8:633–640. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xia D, Holla VR, Wang D, Menter DG and
DuBois RN: HEF1 is a crucial mediator of the proliferative effects
of prostaglandin E(2) on colon cancer cells. Cancer Res.
70:824–831. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Izumchenko E, Singh MK, Plotnikova OV,
Tikhmyanova N, Little JL, Serebriiskii IG, Seo S, Kurokawa M,
Egleston BL, Klein-Szanto A, et al: NEDD9 promotes oncogenic
signaling in mammary tumor development. Cancer Res. 69:7198–7206.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chang JX, Gao F, Zhao GQ and Zhang GJ:
Role of NEDD9 in invasion and metastasis of lung adenocarcinoma.
Exp Ther Med. 4:795–800. 2012.PubMed/NCBI
|
|
27
|
McLaughlin SL, Ice RJ, Rajulapati A,
Kozyulina PY, Livengood RH, Kozyreva VK, Loskutov YV, Culp MV, Weed
SA, Ivanov AV and Pugacheva EN: NEDD9 depletion leads to MMP14
inactivation by TIMP2 and prevents invasion and metastasis. Mol
Cancer Res. 12:69–81. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ice RJ, McLaughlin SL, Livengood RH, Culp
MV, Eddy ER, Ivanov AV and Pugacheva EN: NEDD9 depletion
destabilizes Aurora A kinase and heightens the efficacy of Aurora A
inhibitors: Implications for treatment of metastatic solid tumors.
Cancer Res. 73:3168–3180. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Iida J, Dorchak J, Clancy R, Slavik J,
Ellsworth R, Katagiri Y, Pugacheva EN, van Kuppevelt TH, Mural RJ,
Cutler ML and Shriver CD: Role for chondroitin sulfate
glycosaminoglycan in NEDD9-mediated breast cancer cell growth. Exp
Cell Res. 330:358–370. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bruix J and Llovet JM: Prognostic
prediction and treatment strategy in hepatocellular carcinoma.
Hepatology. 35:519–524. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Witjes CD, van Aalten SM, Steyerberg EW,
Borsboom GJ, de Man RA, Verhoef C and Ijzermans JN: Recently
introduced biomarkers for screening of hepatocellular carcinoma: A
systematic review and meta-analysis. Hepatol Int. 7:59–64. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kitai S, Kudo M, Minami Y, Ueshima K,
Chung H, Hagiwara S, Inoue T, Ishikawa E, Takahashi S, Asakuma Y,
et al: A new prognostic staging system for hepatocellular
carcinoma: Value of the biomarker combined Japan integrated staging
score. Intervirology. 51((Suppl 1)): S86–S94. 2008. View Article : Google Scholar
|
|
33
|
Nishikawa H, Kita R, Kimura T, Endo M,
Ohara Y, Sakamoto A, Saito S, Nishijima N, Nasu A, Komekado H and
Osaki Y: Proposal of the performance status combined Japan
integrated staging system in hepatocellular carcinoma complicated
with cirrhosis. Int J Oncol. 46:2371–2379. 2015.PubMed/NCBI
|
